Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients

Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Hosts: Veda Giri, MD and Todd Morgan, MD CME Available: auau.auanet.org/node/37313 At the conclusion of this activity, participants will be able to 1. Assess how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer while avoiding unnecessary biopsies and detection of clinically unimportant cancers. 2. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used. 3. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme